SCHEMBL6316304

SCHEMBL6316304

Cc1[nH]c2ccc(CCOS(C)(=O)=O)cc2c1C(=O)OC(C)c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.39
PTGS1 P23219 2/20 0.39
PTGS2 P35354 2/20 0.39
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPK14 Q16539 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
EGFR P00533 1/20 0.35
CDK2 P24941 1/20 0.35
TP53 P04637 2/20 0.34
MAPT P10636 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 1/20 0.34
TBXAS1 P24557 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314919 0.83 GAA (0.41) GAALMNASMN1; SMN2MAPK14NPC1
SCHEMBL6315981 0.83 GAA (0.41) GAALMNASMN1; SMN2MAPK14NPC1
SCHEMBL6314259 0.81 MET (0.41) GAALMNASMN1; SMN2MAPK14KMT2A
SCHEMBL6321106 0.80 MET (0.41) GAALMNASMN1; SMN2MAPK14KMT2A
SCHEMBL6316946 0.79 GAA (0.42) GAALMNAMEN1KMT2AMAPT
SCHEMBL6316297 0.78 MAPK14 (0.40) GAAPTGS1PTGS2LMNASMN1; SMN2
SCHEMBL6316385 0.76 GAA (0.49) GAALMNASMN1; SMN2NPC1RAB9A
SCHEMBL6315749 0.74 GAA (0.42) GAALMNASMN1; SMN2TP53MAPT
SCHEMBL6317050 0.73 ALOX5 (0.43) GAAPTGS1PTGS2LMNASMN1; SMN2
SCHEMBL6318404 0.73 GAA (0.39) GAALMNASMN1; SMN2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951848-B2 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC., (US) 2005-10-04 US disclosed
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
EP-1377549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR Millennium Pharmaceuticals, Inc. (US) 2004-01-07 EP disclosed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US disclosed
WO-2002072549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 GAA 3980/4885PTGS1 419/4885PTGS2 1359/4885
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 GAA 3668/4885PTGS1 551/4885PTGS2 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.